Cetuximab may be beneficial beyond progression in certain patients with mCRC
the ONA take:
According to new findings presented at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain, researchers have found that continuing second-line cetuximab beyond progression following first-line chemotherapy and an anti-epidermal growth factor receptor (EGFR) monoclonal antibody is beneficial for patients with metastatic colorectal cancer who do not have KRAS, NRAS, BRAF, or PIK3CA gene mutations.
For the phase II study, researchers enrolled 340 patients with metastatic colorectal cancer and KRAS exon 2 wild-type tumors. All participants received first-line treatment with FOLFIRI plus cetuximab until unacceptable toxicity or disease progression. Those who experienced disease progression were then randomly assigned 1:1 to receive second-line FOLFOX plus cetuximab or FOLFOX alone.
Results showed that patients with quadruple wild-type metastatic colorectal cancer had significantly improved progression-free survival, improved overall survival, and improved response rates with the addition of second-line cetuximab. These patients were most likely to have an EGFR-dependent tumor.
The authors note that further studies are warranted to confirm these findings in a larger patient population.
Continuing second-line cetuximab beyond progression following first-line chemo and an anti-EGFR monoclonal antibody is beneficial for quadruple wild-type metastatic
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|